(OABI) OmniAb, Inc. Business Model Canvas Research

Contract research organizations give OmniAb access to extra screening, assay, and analytics capacity, so partner projects can move from antibody hits to lead candidates faster. Outsourced workflows also add operating flexibility, which matters when programs need to scale up or down without adding fixed lab costs.

• More screening throughput
• Faster hit-to-lead conversion
• Higher workflow flexibility

OmniAb relies on specialized technology and service vendors for lab supplies, animal models, and data tools that keep assay work, reagent flow, and uptime steady. These partners matter because platform scale depends on uninterrupted access to critical inputs across discovery and validation.

Reliable vendor support helps OmniAb protect throughput and avoid delays; even short gaps in reagents or animal services can slow programs and raise costs.

• Supports assay infrastructure
• Supplies reagents and models
• Protects operational continuity
• Enables higher throughput

OmniAb’s bispecific and hard-target work centers on OmniFlic and OmniClic for common-light-chain bispecific antibody design, plus OmniTaur for tough targets using cow antibody biology. This expands the platform beyond standard monoclonal discovery and supports a broader pipeline across complex targets.

• OmniFlic and OmniClic support bispecific design
• OmniTaur helps reach hard targets
• Platform goes beyond monoclonals

OmniAb, Inc. manages partner discovery programs end to end, from target intake to hit selection, with tight technical communication, data transfer, and milestone tracking. Strong execution keeps alliance trust high and helps protect long-term partner value.

• Target intake to hit selection
• Technical updates and data transfer
• Milestone tracking and alliance retention

OmniAb’s patent estate and IP rights are core key resources: they protect the engineered animals and platform methods, support licensing leverage, and give partners confidence to pay for access. This is what keeps the technology differentiated and harder to copy.

• Protects engineered animals and methods
• Strengthens partner trust in access rights
• Supports licensing pricing power

OmniAb, Inc.'s scientific team of biology, immunology, and platform scientists is central to turning discovery into partner-ready programs. Its lab infrastructure supports animal maintenance and screening, while experienced operators move platform assets into commercial deals and royalty-generating assets.

• Biology and immunology drive assay design.
• Labs support animal and screening workflows.
• Operational know-how converts assets to programs.

OmniTaur uses cow antibody structure to reach hard-to-hit epitopes that standard antibodies often miss, widening the target set for partners. This matters because nontraditional antibody formats can open programs in targets that are still out of reach for conventional discovery.

• Hard-to-hit epitopes
• Nontraditional antibody formats
• Broader partner target universe

OmniAb, Inc.’s partnered discovery model gives customers rapid access to antibody discovery capacity without paying to build the full lab stack, staff, and tools in-house. That cuts startup spend and shortens timelines, which matters when faster lead selection can shape winner-take-most therapeutic programs.

• Less upfront capital
• Faster discovery cycles
• Built for competitive drug races

OmniAb, Inc.'s confidential co-development model fits antibody work, where target data, assay results, and lead sequences are highly sensitive. Protecting partner IP with strict confidentiality, controlled data sharing, and clear ownership terms helps keep trust high, and trust is what keeps long-cycle discovery programs in place.

• Protects target and sequence IP
• Limits data access and leakage
• Supports retention through trust

OmniAb, Inc. uses a license-and-option structure that can turn early discovery access into broader licensing rights after validation. That gives partners a clear path to expand, and one successful conversion can lift value per program because the relationship can deepen as data de-risks the asset.

• Start with discovery access.
• Expand only after validation.
• Raise value per successful program.

OmniAb, Inc.'s peer-reviewed publications and patent filings help prove its animal discovery systems and screening methods work in real use, not just on slides. Public paper visibility also helps partners judge data quality and platform depth before they sign.

• Supports platform credibility
• Helps explain screening value
• Can shape partner review

Partner referrals matter for OmniAb, Inc. because one successful antibody-discovery collaboration can lead to more programs, repeat work, and new introductions inside a tight biotech network. In a niche where trust and technical fit drive deals, referral momentum cuts sales friction and can speed partner conversion.

• One win can seed repeat business.
• Word-of-mouth lowers acquisition cost.
• Trust matters most in niche biotech.

Bispecific antibody teams developing advanced biologics need common-light-chain and format-enabled discovery tools, and OmniFlic plus OmniClic fit that need. The segment matters because bispecifics are now a proven growth area, with 10+ approved drugs already showing real commercial demand.

• Common-light-chain discovery support
• Format-enabled bispecific design
• Targets fast-growing biologics teams

Hard-target program owners are teams tackling novel or difficult antigens, where standard discovery often misses the biology. OmniAb's OmniTaur platform uses cow antibody structures to reach unusual epitopes, so the segment pays for problem-solving, not commodity discovery.

IP and legal costs are a core burden for OmniAb, Inc.: patent filing, maintenance, and contract drafting protect its engineered-animal platform and licensing terms. That spend helps defend value capture, since U.S. utility patents can run 20 years from filing and legal policing is key to stopping misuse.

• Patents protect platform value.
• Legal work supports license terms.
• Defense helps defend revenue capture.

OmniAb, Inc.’s public company overhead covers finance, audit, SEC reporting, and compliance work, plus general admin support for sales and partner management. These fixed costs are part of running a listed company at scale, and they tend to rise with filings, controls, and partner activity.

• Finance and audit support
• SEC reporting and compliance
• Sales and partner admin

If a partner program reaches approval, OmniAb can earn product royalties on every sale, so one successful therapy can turn into recurring revenue with little added cost. That makes royalties the highest-leverage stream in the model: in pharma, even a low-single-digit to mid-single-digit royalty on net sales can scale fast once a drug gets broad use.

• Royalties start only after commercialization.
• Upside grows with each sold unit.
• One approved product can fund many programs.

Option exercise fees and downstream sublicense participation let OmniAb, Inc. earn beyond discovery work, so a single partner program can keep paying as it advances. In OmniAb, Inc.'s latest filings, this type of income sits beside research fees and milestones and helps turn successful partner assets into longer-tail cash flow.

• Option fees add near-term cash
• Sublicenses capture downstream value
• Best case: repeated partner wins